Boeing (BA) Beats on Q1 Earnings and Revenue Estimates

BA

The Boeing Co. (BA - Free Report) is a premier jet aircraft manufacturer and is also one of the largest defense contractors in the U.S. Its revenue exposure is spread across more than 90 countries around the globe.

In the race for supremacy in the commercial skies, the North American jet plane maker – Boeing − has surpassed its European rival Airbus in 2017 for the sixth consecutive year. Competition between Airbus and Boeing has been characterized as a duopoly in the large jet airliner market since the 1990s.

Estimates Revision & Earnings Surprise Trend

Boeing’s earnings estimate for the first quarter has increased by 3 cents over the past 7 days.

It also has an impressive history in earnings season, reporting positive earnings surprises in the last four quarters with an average beat of 20.69%.

Zacks Rank: Currently, Boeing has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. We have mentioned below some of the vital information from this just-revealed announcement:

Earnings Beat: Our consensus called for earnings of $2.59 and the company reported adjusted earnings per share of $3.64.

Revenue Beat: Revenues also surpassed the expectations. Boeing posted revenues of $23.38 billion, compared to our consensus estimate of $22.32 billion.

Key Stats to Note: Boeing ended the first quarter with total backlog of $486 billion, up from $475 billion at the beginning of 2018.

During the quarter, the company repurchased 8.9 million shares for $3 billion and paid $1 billion in dividends.

Market Reaction: Boeing’s shares moved up about 2.4% in pre-market trading following the release, at the time of this write-up, thereby reflecting investors’ optimism toward this earnings results.

Check back later for our full write up on this Boeing earnings report later!

Investor Alert: Breakthroughs Pending

A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.

Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.

Click here to see them >>

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>